In response to the recent bioboom, physicians may consider switching patients to a biosimilar for a more affordable alternative. However, this is a decision that shouldn’t be made in haste and has a few crucial points to be considered.
Our 2017 Banned & Restricted Cosmetic Ingredients Global Index is a one stop shop for access to a global dossier of cosmetic ingredients regulation resources including a global inventory of prohibited substances, restricted ingredients and a overview of recent regulatory changes.
Recent research conducted by the International Childhood Cancer Cohort Consortium and led by Professor Terry Dwyer of Oxford University has confirmed a link between birthweight and childhood cancer.
What are the secrets to incorporating technology in compound management workflow in a way that makes sense? Perhaps more importantly, what are the benefits the pharma industry can expect to see?
After a decade in development, products in a multi-billion dollar sector are falling at the last hurdle – under-the-gaze of the regulator